RIA
RPRX icon

Regal Investment Advisors’s Royalty Pharma RPRX Stock Holding History

Regal Investment Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.82M Sell
103,861
-3,093
-3% -$161K 0.3% 81
2026
Q1 		$5.13M Sell
106,954
-6,387
-6% -$280K 0.3% 88
2025
Q4 		$4.38M Buy
113,341
+3,617
+3% +$138K 0.26% 97
2025
Q3 		$3.87M Buy
109,724
+16,792
+18% +$608K 0.25% 107
2025
Q2 		$3.35M Sell
92,932
-6,772
-7% -$224K 0.25% 105
2025
Q1 		$3.1M Buy
99,704
+81,989
+463% +$2.6M 0.25% 111
2024
Q4 		$452K Sell
17,715
-11,138
-39% -$295K 0.03% 342
2024
Q3 		$816K Buy
28,853
+7,686
+36% +$213K 0.06% 276
2024
Q2 		$558K Buy
21,167
+3,700
+21% +$103K 0.04% 332
2024
Q1 		$530K Buy
17,467
+7,960
+84% +$235K 0.04% 349
2023
Q4 		$267K Buy
+9,507
New +$261K 0.02% 444
2023
Q2 		– Sell
-5,749
Closed -$207K – 543
2023
Q1 		$207K Buy
5,749
+29
+0.5% +$1.07K 0.02% 477
2022
Q4 		$226K Buy
5,720
+270
+5% +$11.3K 0.02% 431
2022
Q3 		$219K Buy
+5,450
New +$233K 0.02% 427

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Regal Investment Advisors's RPRX Position: Q2 2026 in Review

Regal Investment Advisors reduced its Royalty Pharma (RPRX) stake by 2.9% in Q2 2026, selling an estimated $161K and leaving 103,861 shares worth $5.82M. The position accounts for 0.3% of the portfolio, ranked #81.

Regal Investment Advisors first reported a position in RPRX in Q3 2022 and has held it in 14 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Regal Investment Advisors held 103,861 shares of Royalty Pharma worth $5.82M as of Q2 2026.
  • Regal Investment Advisors sold 3,093 Royalty Pharma shares in Q2 2026, an estimated $161K.
  • Royalty Pharma made up 0.3% of Regal Investment Advisors's portfolio in Q2 2026, its #81 holding.
  • Regal Investment Advisors first reported a position in Royalty Pharma in Q3 2022 and has held it in 14 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Regal Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.